{"title":"Arenobufagin Induces Ferroptosis in Glioblastoma Cells via Modulating the MiR-149-5p/AEBP1 Axis.","authors":"Renzhi Hu, Sisi Tang, Yanrui Xiang, Shuyong Qin","doi":"10.1002/jat.4732","DOIUrl":null,"url":null,"abstract":"<p><p>Accumulating evidences have proved Arenobufagin (ArBu) exhibited cytotoxic effects to multiple types of cancer. However, in glwioblastoma (GBM), which is easy to develop resistance to classic chemotherapy reagent, the therapeutic effects of ArBu have not been explored. In the current study, we found that GBM cells were sensitive to ArBu treatment and ArBu induced cell death both in a dose-dependent and a time-dependent manner. ArBu was observed to promote ROS accumulating and elevate Fe<sup>2+</sup>/MDA/GSH level, which lead to ferroptosis. Mechanistically, ArBu significantly downregulated AEBP1 expression and decreased the mRNA stability of AEBP1 without affecting its transcription. Then, AEBP1 mRNA was predicted to bind with miR-149-5p in GBM cells, which directly target its 3'UTR. At last, we found ArBu could upregulate miR-149-5p to suppress AEBP1 expression, and the rescue experiments confirmed miR-149-5p/AEBP1 axis regulated ferroptosis, which underlay the therapeutic effects of ArBu in GBM cells. This study revealed that ArBu induced ferroptosis in a dose-dependent manner via modulating miR-149-5p/AEBP1 axis. It provides evidences for clinical application of ArBu for GBM.</p>","PeriodicalId":15242,"journal":{"name":"Journal of Applied Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jat.4732","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Accumulating evidences have proved Arenobufagin (ArBu) exhibited cytotoxic effects to multiple types of cancer. However, in glwioblastoma (GBM), which is easy to develop resistance to classic chemotherapy reagent, the therapeutic effects of ArBu have not been explored. In the current study, we found that GBM cells were sensitive to ArBu treatment and ArBu induced cell death both in a dose-dependent and a time-dependent manner. ArBu was observed to promote ROS accumulating and elevate Fe2+/MDA/GSH level, which lead to ferroptosis. Mechanistically, ArBu significantly downregulated AEBP1 expression and decreased the mRNA stability of AEBP1 without affecting its transcription. Then, AEBP1 mRNA was predicted to bind with miR-149-5p in GBM cells, which directly target its 3'UTR. At last, we found ArBu could upregulate miR-149-5p to suppress AEBP1 expression, and the rescue experiments confirmed miR-149-5p/AEBP1 axis regulated ferroptosis, which underlay the therapeutic effects of ArBu in GBM cells. This study revealed that ArBu induced ferroptosis in a dose-dependent manner via modulating miR-149-5p/AEBP1 axis. It provides evidences for clinical application of ArBu for GBM.
期刊介绍:
Journal of Applied Toxicology publishes peer-reviewed original reviews and hypothesis-driven research articles on mechanistic, fundamental and applied research relating to the toxicity of drugs and chemicals at the molecular, cellular, tissue, target organ and whole body level in vivo (by all relevant routes of exposure) and in vitro / ex vivo. All aspects of toxicology are covered (including but not limited to nanotoxicology, genomics and proteomics, teratogenesis, carcinogenesis, mutagenesis, reproductive and endocrine toxicology, toxicopathology, target organ toxicity, systems toxicity (eg immunotoxicity), neurobehavioral toxicology, mechanistic studies, biochemical and molecular toxicology, novel biomarkers, pharmacokinetics/PBPK, risk assessment and environmental health studies) and emphasis is given to papers of clear application to human health, and/or advance mechanistic understanding and/or provide significant contributions and impact to their field.